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Abstract
Pseudomonas aeruginosa status influences cystic fibrosis (CF) clinical management but no ‘gold standard’ definition
exists. The Leeds criteria are commonly used but may lack sensitivity for chronic P. aeruginosa. We compared
clinicians’ decision with the Leeds criteria in three adult CF centres. Two independent prospective datasets
(Sheffield dataset, n = 185 adults; ACtiF pilot dataset, n = 62 adults from two different centres) were analysed.
Clinicians involved in deciding P. aeruginosa status were blinded to the study objectives. Clinicians considered
more adults with CF to have chronic P. aeruginosa infection compared to the Leeds criteria. This was more so for
the Sheffield dataset (106/185, 57.3% with clinicians’ decision vs. 80/185, 43.2% with the Leeds criteria; kappa
coefficient between these two methods 0.72) compared to the ACtiF pilot dataset (34/62, 54.8% with clinicians’
decision vs. 30/62, 48.4% with the Leeds criteria; kappa coefficient between these two methods 0.82). However,
clinicians across different centres were relatively consistent once age and severity of lung disease, as indicated by
the type of respiratory samples provided, were taken into account. Agreement in P. aeruginosa status was similar
for both datasets among adults who predominantly provided sputum samples (kappa coefficient 0.78) or adults
> 25 years old (kappa coefficient 0.82). Across three different centres, clinicians did not always agree with the
Leeds criteria and tended to consider the Leeds criteria to lack sensitivity. Where disagreement occurred, clinicians
tended to diagnose chronic P. aeruginosa infection because other relevant information was considered. These
results suggest that a better definition for chronic P. aeruginosa might be developed by using consensus methods
to move beyond a definition wholly dependent on standard microbiological results.
Introduction
Cystic fibrosis (CF), an autosomal recessive genetic condition,
affects around 10,000 people in the UK [1]. It is a multi-
system condition; lungs (resulting in recurrent infections and
respiratory failure) and the gastrointestinal tract (resulting in
malabsorption of fat and poor growth) are the two main af-
fected organs.
Pseudomonas aeruginosa remains the most common
chronic lung pathogen among adults with CF, despite changes
in pathogen epidemiology [1, 2]. Once acquired,
P. aeruginosa infection is associated with increased risk of
pulmonary exacerbations and accelerated lung function de-
cline [3]. Early eradication therapy mitigates lung function
decline and delays onset of chronic infection [4], while long-
term inhaled antibiotics reduce the risk of exacerbation and
improves lung function in those with chronic P. aeruginosa
infection [5]. Pseudomonas aeruginosa status influences
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various clinical decisions in CF [5–7]. During clinic reviews
and in-patient stays, adults with CF not infected by
P. aeruginosa are segregated from those with P. aeruginosa
infection to prevent cross-infection [7]. Adults with CF
deemed to have chronic P. aeruginosa infection should be
treated with long-term inhaled anti-pseudomonal antibiotics
[5], because chronic P. aeruginosa infection is associated with
accelerated lung function decline. They should also be treated
with appropriately broad spectrum intravenous antibiotics
during pulmonary exacerbations [7, 8], due to the resistance
pattern of P. aeruginosa. Careful monitoring of P. aeruginosa
status is, hence, an important standard of care in CF [8].
However, there is no ‘gold standard’ to define
P. aeruginosa status among adults with CF. One of the most
commonly used definitions in CF research are the Leeds
criteria [7]. These criteria define Bchronic P. aeruginosa
infection^ as > 50% of months with cough swabs/sputum
cultures in the preceding 12 months that were positive for
P. aeruginosa [7]. For example, if an adult provided nine
sputum samples over seven months in the last year and
P. aeruginosawas cultured in four of those months, that would
be considered as chronic P. aeruginosa. BIntermittent
P. aeruginosa infection^was defined as ≤ 50% ofmonths with
positive P. aeruginosa culture. In the above example, if only
three of those months have at least one positive P. aeruginosa
culture, that would be considered as intermittent
P. aeruginosa, even if majority of the samples (e.g. five of
nine) were positive for P. aeruginosa. Therein lies the advan-
tage of the Leeds criteria over other definitions, e.g. Ballmann
et al.’s definition of chronic P. aeruginosa as > 50% of cough
swabs/sputum cultures being P. aeruginosa positive in a 12-
month period [9]. If there is a new positive culture for
P. aeruginosa, more samples might be taken within a short
interval, especially if there was admission for intravenous an-
tibiotics as part of the eradication regime. More intensive
monitoring could bias towards misclassifying intermittent
P. aeruginosa as chronic if the timings of samples taken were
not considered.
Whilst the Leeds criteria are very specific for chronic
P. aeruginosa infection, recent studies using polymerase chain
reaction (PCR) techniques have shown that the Leeds criteria
are insensitive, with a tendency to under-diagnose chronic
P. aeruginosa as intermittent infection [10, 11]. A particular
issue is the equal weighting given to cough swabs and sputum
samples, even though a cough swab is less sensitive in cultur-
ing P. aeruginosa [12, 13]. In addition, the Leeds criteria do
not consider other key information, such as P. aeruginosa
strain typing or results of other investigations, e.g. serum
P. aeruginosa antibody levels [14]. For example, resistant ep-
idemic strains are less likely to be cleared than unique envi-
ronmental strains [15]. In their day-to-day work, it is likely
that clinicians assimilate all of this relevant information in
making a decision about P. aeruginosa status.
However, how clinicians reach a decision on P. aeruginosa
status has not been formally investigated. It is also important
to understand how different approaches to the definition of
P. aeruginosa status will affect reported prevalence within
routine datasets, such as the UK CF Registry. Using two in-
dependent prospective datasets, we set out to compare the
distribution of P. aeruginosa status as judged by clinicians
with the distribution defined by the Leeds criteria. We also
systematically compared clinicians’ decisions against the
Leeds criteria to identify subgroups of adults where clinicians
are more likely to disagree with the Leeds criteria.
Materials and methods
Design and setting
This is a cross-sectional analysis of prospectively collected
data from two independent datasets and includes clinicians
from three adult CF centres.
The first dataset included every eligible adult receiving care
at the Sheffield Adult Cystic Fibrosis Centre in 2015 (n =
185). Regulatory approval to analyse data from this dataset
was obtained from NHS Health Research Authority (IRAS
number 210313).
The second dataset included every eligible participant in
the ACtiF pilot study. Participants were recruited from the
East Midlands Wolfson Cystic Fibrosis Centre (n = 31) and
the Wessex Adult Cystic Fibrosis Centre (n = 31). This is a
randomised controlled external pilot trial to evaluate the fea-
sibility for a full-scale randomized controlled trial (RCT) of a
theory-based complex intervention to support self-care and
adherence with inhaled therapies (ISRCTN13076797).
Regulatory approval for the pilot was obtained from Brent
Research Ethics Committee (REC reference 16/LO/0356).
Patients with lung transplantation or who were on ivacaftor
were excluded. Lung transplantation changes lung
microbiome, which complicates the interpretation of
P. aeruginosa status [16]. Ivacaftor reduces the likelihood of
culturingP. aeruginosa, which may affect the diagnostic prop-
erties of the Leeds criteria [17].
Data collection
For the Sheffield dataset, two experienced CF physicians
(FPE, RC) independently reviewed all relevant patient data
up to December 2015 to decide on the P. aeruginosa status
(‘no P. aeruginosa’, ‘intermittent’, ‘chronic’). If agreement
was achieved at this stage, it was accepted as the clinicians’
status. If agreement was not achieved, the P. aeruginosa status
was decided in a consensus meeting by both physicians and a
microbiologist with CF experience (LP), whereby all three
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clinicians agreed on the final clinicians’ status. The following
data for 2015 were obtained from electronic patient records:
& Microbiology: every cough swab and sputum sample in
2015
& Demographics: age, gender, pancreatic status, presence of
CF-related diabetes, socioeconomic status (postcodes
were used to derive the Index of Multiple Deprivation,
IMD [18])
& Body mass index, BMI (in kg/m2)
& %FEV1 (calculated with the Knudson equation [19])
& Annual intravenous antibiotic days (in number of days)
For the ACtiF pilot dataset, an experienced CF physician at
each centre (JD at the East Midlands Wolfson Cystic Fibrosis
Centre; MIA or JAN at the Wessex Adult Cystic Fibrosis
Centre) reviewed all relevant patient data up to the point of
participant recruitment to decide on P. aeruginosa status. A
similar set of data to the Sheffield dataset was collected at the
point of recruitment from June to September 2016.
Participants’ %FEV1 at baseline was calculated using the
Global Lung Function Initiative (GLI) equation [20].
All clinicians involved in deciding the P. aeruginosa status
were blinded to the study objectives and analyses plan to
minimise bias. Across all sites, microbiology samples were
collected during every clinical review, and care standards dic-
tate that the interval between reviews should be ≤ 3 months.
Pseudomonas aeruginosa was isolated from samples in the
respective nationally accredited microbiology laboratories in
Sheffield, Nottingham, Southampton and Poole using stan-
dard methods in accordance to national guidelines [21].
Data analysis
In this analysis, the Leeds criteria categories of ‘free from
infection’ and ‘never’ were combined into a single category
(‘no P. aeruginosa’) because both these categories are typical-
ly treated in the same manner among adults with CF. This
produced three categories of P. aeruginosa status, i.e. ‘no
P. aeruginosa’ if no growth of P. aeruginosa in cough
swabs/sputum cultures during the previous 12 months; ‘inter-
mittent’ if P. aeruginosa positive in ≤ 50% of months when
cough swabs/sputum cultures had been taken; and ‘chronic’ if
P. aeruginosa positive in > 50% of months when cough
swabs/sputum cultures had been taken.
Data from the Sheffield and ACtiF pilot datasets were
analysed separately. Reasons for every clinicians’ decision in
the Sheffield dataset were recorded and thematically analysed
to understand the basis of clinicians’ decision-making.
For both datasets, appropriate descriptive statistics were
generated, including cross-tabulation of the Leeds criteria
P. aeruginosa categories against clinicians’ decision.
Agreement between clinicians’ decision and the Leeds criteria
were determined using kappa statistics [22]. Sensitivity, spec-
ificity and likelihood ratios of the Leeds criteria in diagnosing
chronic P. aeruginosa were calculated using clinicians’ deci-
sion as the reference. Likelihood ratios were calculated instead
of predictive values because likelihood ratios are independent
of prevalence, hence comparable between the two datasets
[23].
Clinical characteristics for the group in which the
P. aeruginosa status differed between clinicians’ decision
and the Leeds criteria were compared using non-parametric
methods against the group where there was agreement, to
identify the subgroups of adults whereby the P. aeruginosa
status is more contentious.
All analyses were performed using SPSS Statistics v22
(IBM Corp.), with p-values < 0.05 considered statistically
significant.
Results
For the Sheffield dataset, 185 adults were included, with me-
dian age of 27 years [interquartile range (IQR) 20–34 years].
A total of 1211 relevant respiratory samples were collected
during 2015 (750 sputum samples, 461 cough swabs). For
the ACtiF pilot dataset, 62 adults were included, with median
age of 28 years (IQR 22–37 years). A total of 528 relevant
respiratory samples were collected in a one-year period prior
to recruitment (491 sputum samples, 37 cough swabs). The
ACtiF pilot participants have more severe lung disease, even
after allowing for the difference in %FEV1 measurements,
which is, in part, due to the eligibility criteria of the ACtiF
pilot. To be eligible, participants must be on long-term inhaled
therapies and this selected for adults with more severe lung
disease. Not surprisingly, the average number of respiratory
samples collected from the ACtiF pilot was higher and pre-
dominantly sputum, whereas the Sheffield study subjects with
less severe lung disease produced far more cough swabs (see
Table 1).
In both datasets, more adults have chronic P. aeruginosa
infection according to clinicians’ decision compared to the
Leeds criteria. This was more so for the Sheffield dataset
(106/185, 57.3% with clinicians’ decision vs. 80/185, 43.2%
with the Leeds criteria) compared to the ACtiF pilot dataset
(34/62, 54.8% with clinicians’ decision vs. 30/62, 48.4% with
the Leeds criteria). Where there was disagreement in
P. aeruginosa status, the clinicians tended to diagnose chronic
P. aeruginosa infection, but the Leeds criteria diagnosed no or
intermittent P. aeruginosa (see Tables 2 and 3). For example,
21 adults in the Sheffield dataset fulfilled the Leeds criteria for
‘intermittent P. aeruginosa’ but were deemed by clinicians to
have ‘chronic P. aeruginosa’. This disagreement was, in part,
driven by clinicians placing different weighting on cough
swabs compared to sputum samples, and clinicians diagnosed
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chronic P. aeruginosa infection even if P. aeruginosawas less
frequently cultured on cough swabs, i.e. cough swabs with no
growths tended to be ignored (see the reasons provided by
Sheffield clinicians for diagnosing chronic P. aeruginosa in
Table 4).
In the Sheffield dataset, the most obvious differences be-
tween adults with discordant and concordant P. aeruginosa
status were the numbers of cough swabs and sputum samples.
The discordant group were also younger (see Table 5). This
would account for the minor differences in BMI and %FEV1
Table 2 Pseudomonas aeruginosa status according to clinicians’ decision vs. the Leeds criteria
Leeds criteria P. aeruginosa status,
number of adults
Sheffield dataseta (n = 185) P. aeruginosa status
according to clinicians’ decision, number of adults
ACtiF pilot datasetb (n = 62) P. aeruginosa status
according to clinicians’ decision, number of adults
No
P. aeruginosa
Intermittent
P. aeruginosa
Chronic
P. aeruginosa
No
P. aeruginosa
Intermittent
P. aeruginosa
Chronic
P. aeruginosa
No P. aeruginosa 64 5 5 21 1 2
Intermittent P. aeruginosa 0 10 21 1 4 3
Chronic P. aeruginosa 0 0 80 0 1 29
a Cohen’s kappa coefficient of 0.72 [95% confidence interval (CI) 0.64–0.80] between clinicians’ decision and the Leeds criteria for the Sheffield dataset
b Cohen’s kappa coefficient of 0.82 (95% CI 0.74–0.89) between clinicians’ decision and the Leeds criteria for the ACtiF pilot dataset
Table 1 Demographic and clinical characteristics of the study subjects
Sheffield dataseta (n = 185) ACtiF pilot dataset (n = 62)
Age in years, median (IQR) 27 (20–34) 28 (22–37)
Females (%) 87 (47.0) 26 (41.9)
Pancreatic insufficient (%) 142 (76.8) 54 (87.1)
CF-related diabetes (%) 42 (22.7) 28 (45.2)
Social deprivation (IMD quintile)
1 (least deprived) (%) 28 (15.1) 15 (24.2)
2 (%) 16 (8.6) 14 (22.6)
3 (%) 43 (23.2) 15 (24.2)
4 (%) 44 (23.8) 11 (17.7)
5 (most deprived) (%) 54 (29.3) 7 (11.3)
Number of relevant microbiological samples
Cough swabs, median (IQR) 2 (0–4) 0 (0–0)
Sputum samples, median (IQR) 3 (1–7) 8 (5–10)
Total, median (IQR) 6 (4–9) 8 (6–10)
Pseudomonas aeruginosa status (Leeds criteria)
Chronic P. aeruginosa (%) 80 (43.2) 30 (48.4)
Intermittent P. aeruginosa (%) 31 (16.8) 8 (12.9)
No P. aeruginosa (%) 74 (40.0) 24 (38.7)
Pseudomonas aeruginosa status (clinicians’ decision)
Chronic P. aeruginosa (%) 106 (57.3) 34 (54.8)
Intermittent P. aeruginosa (%) 15 (8.1) 6 (9.7)
No P. aeruginosa (%) 64 (34.6) 22 (35.5)
BMI in kg/m2, median (IQR) 23.0 (20.3–26.0) 22.2 (19.6–25.4)
% predicted FEV1, median (IQR) 81 (63–93)
b 51.2 (42.9–77.9)c
Annual intravenous antibiotic days, median (IQR) 14 (0–35) 17 (5–44)
a Complete data were available for every clinical variable in the Sheffield dataset, except for one study subject who did not have any FEV1 readings in
2015 due to inability to perform spirometry testing. Complete data were available for every clinical variable in the ACtiF pilot dataset
b This is the highest FEV1 obtained in 2015. % predicted is calculated using the Knudson equation
c This is the baseline FEV1 at recruitment to the ACtiF pilot. % predicted is calculated using the GLI equation
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between these two groups. The smaller sample size and more
homogenous nature of the ACtiF pilot dataset made it more
difficult to detect differences between adults with discordant
versus concordant P. aeruginosa status. Nonetheless, the dif-
ferences in age and %FEV1 were in the same direction as the
Sheffield dataset, suggesting some consistency in the
decision-making by different clinicians across three CF cen-
tres. These differences allowed the identification of two broad
subgroups in which clinicians were more likely to disagree
with the Leeds criteria: (1) those who provided more cough
swabs than sputum samples and (2) younger adults
(≤ 25 years).
Most of the discrepancies between clinicians and the Leeds
criteria in both datasets were driven by these ‘more difficult to
agree’ subgroups (see Table 6). The extent by which clinicians
diagnosed more chronic P. aeruginosa in relation to the Leeds
criteria were actually very similar across both datasets among
adults who provided at least an equal number of sputum sam-
ples as cough swabs, or older adults (i.e. the ‘easier to agree’
subgroups). Among adults > 25 years old who provided at
least an equal number of sputum samples as cough swabs,
the difference in the proportion of adults with chronic
P. aeruginosa according to clinicians versus the Leeds criteria
were similar for both datasets (Sheffield: 59/74, 79.7% with
clinicians’ decision vs. 54/74, 73.0% with the Leeds criteria;
ACtiF pilot: 22/36, 61.1% with clinicians’ decision vs. 20/36,
55.6% with the Leeds criteria).
Discussion
Although P. aeruginosa status and management decisions re-
lated to P. aeruginosa status are often decided by clinicians in
routine clinical practice, this is the first study that formally
evaluates clinicians’ diagnosis of P. aeruginosa status among
adults with CF. This study demonstrated that clinicians diag-
nosed chronic P. aeruginosa when the Leeds criteria did not,
partly because clinicians placed less importance on negative
cough swabs, and, in the face of negative cough swabs, inte-
grated other relevant information to decide on P. aeruginosa
status. On the other hand, the Leeds criteria depend solely on
standard microbiological results and ignore other key infor-
mation, such as P. aeruginosa strain typing.
This finding is consistent with previous studies which
found cough swabs less sensitive in culturing P. aeruginosa
[12, 13] and the Leeds criteria lacking in sensitivity for chron-
ic P. aeruginosa when compared against PCR methods [10,
11]. Indeed, quantitative PCR assays often detect
P. aeruginosa when bacterial cultures are negative [24];
hence, a negative culture does not always imply the absence
of P. aeruginosa infection and intermittent positive
P. aeruginosa cultures do not always imply intermittent
infection.
It may appear that Sheffield clinicians diagnosed far more
chronic P. aeruginosa cases versus the Leeds criteria in com-
parison to the ACtiF pilot clinicians. However, the observed
discrepancy was largely driven by the differences in the case
mix (age and severity of lung disease, as indicated by the type
of respiratory samples provided) between the two datasets.
Among the subgroups in which agreement between clinicians’
decision and the Leeds criteria were more likely (i.e. older
adults or adults who provided at least equal numbers of spu-
tum samples to cough swabs), the discrepancies between the
Leeds criteria and clinicians’ decision for both datasets were
Table 4 Reasons provided by Sheffield clinicians for deciding when an
adult with cystic fibrosis (CF) has chronic P. aeruginosa infection
Clinicians’ basis for chronic P. aeruginosa infection
Multiple positive samples (≥ 3 months with positive samples in a year)
If cough swab only, at least two positive cough swabs in a year
Accept as chronic P. aeruginosa infection even with negative samples, if
poor quality respiratory samplea and high serum P. aeruginosa
antibody levels
Accept as chronic P. aeruginosa infection even with negative samples, if
high adherence to inhaled antibiotics
Accept as chronic P. aeruginosa infection even with negative samples, if
clinically deteriorates with cessation of inhaled antibiotics
Transmissible strain difficult to eradicate, so accept as chronic
P. aeruginosa infection if cultured within the last 12–18 months
Mucoid Pseudomonas difficult to eradicate, so accept as chronic
P. aeruginosa infection if cultured within the last 12–18 months
Two separate positive cultures ofP. aeruginosa > 1 year apart of the same
strain
Long previous history of P. aeruginosa infection (first positive culture
> 5 years ago), with ≥ 2 positive P. aeruginosa cultures > 1 year apart
a A particular respiratory sample (cough swab/sputum sample) was
deemed as possibly ‘poor quality’ if no other known CF pathogens, e.g.
Haemophilus influenzae, was cultured from that sample
Table 3 Diagnostic properties of
the Leeds criteria for ‘chronic
P. aeruginosa infection’, in
comparison to clinicians’ decision
Sheffield dataset
(n = 185)
ACtiF pilot dataset
(n = 62)
Sensitivity (95% CI) 0.75 (0.66–0.83) 0.85 (0.69–0.95)
Specificity (95% CI) 1.00 (0.94–1.00) 0.96 (0.82–1.00)
Positive likelihood ratio (95% CI) Infinity 23.88 (3.47–164.49)
Negative likelihood ratio (95% CI) 0.25 (0.18–0.34) 0.15 (0.07–0.34)
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very similar, suggesting a degree of consistent decision-
making by clinicians from three different specialist adult CF
centres in the UK. Clinicians involved in deciding
P. aeruginosa status were blinded to the study objectives
and analyses plan to minimise bias. The results from three
centres were compared in this study, helping us to gain insight
into patterns across adult UK centres rather than the peculiar-
ities specific to a single centre.
Limitations of this study should be acknowledged. The
limited number of study subjects with ‘discordant
P. aeruginosa status’ meant that multivariate logistic regres-
sion could not be used to analyse differences in clinical char-
acteristics between the discordant and concordant groups.
Data on whether respiratory samples were collected during
periods on or off anti-pseudomonal antibiotics were not col-
lected, and, therefore, we could not explore whether this is a
specific factor that causes discordance between clinicians’ de-
cision and the Leeds criteria. Pseudomonas aeruginosa was
isolated from respiratory samples using standard
Pseudomonas isolation agar, as recommended by national
guidelines [21], but more sensitive culture methods, e.g. quan-
titative cultures, may well increase the proportion of adults
diagnosed with chronic P. aeruginosa infection according to
the Leeds criteria. However, evaluation of novel culture
methods that are not routinely available is beyond the scope
of this pragmatic study. In the two ACtiF pilot centres, a single
clinician decided on the P. aeruginosa status of participants
recruited to the study after considering relevant data without a
consensus process involving other clinicians, whereas
Sheffield clinicians made decisions across the whole centre
population with a relatively structured process involving in-
dependent consideration by two clinicians, followed by final
consensus involving a third clinician. The Sheffield process
allowed more detailed exploration of the challenge of deter-
mining P. aeruginosa status in the real world. For example,
clinical deterioration after cessation of inhaled antibiotics de-
spite negative samples. However, these ‘subjective’ reasons
were only applied to a small minority of study subjects and
Table 5 Demographic and clinical characteristics for study subjects with discordant vs. concordant P. aeruginosa status between clinicians’ decision
and the Leeds criteria
Sheffield dataset ACtiF pilot dataset
Discordant
P. aeruginosa
status (n = 31)
Concordant
P. aeruginosa
status (n = 154)
p-Value Discordant P.
aeruginosa
status (n = 8)
Concordant P.
aeruginosa
status (n = 54)
p-Value
Age in years, median (IQR) 20 (18–26) 27 (22–34) 0.001* 25 (22–31) 28 (22–38) 0.266*
Females (%) 15 (48.4) 72 (46.8) 0.868*** 3 (37.5) 23 (42.6) 1.000****
Pancreatic insufficient (%) 30 (96.8) 112 (72.7) 0.004*** 8 (100.0) 46 (85.2) 0.581****
CF-related diabetes (%) 5 (16.1) 37 (24.0) 0.338*** 3 (37.5) 25 (46.3) 0.719****
Social deprivation (IMD quintile)
1 (least deprived) (%) 7 (22.6) 22 (14.3) 0.265** 1 (12.5) 14 (25.9) 0.875**
2 (%) 1 (3.1) 15 (9.7) 2 (25.0) 12 (22.2)
3 (%) 10 (32.3) 33 (21.4) 4 (50.0) 11 (20.4)
4 (%) 6 (19.4) 37 (24.1) 1 (25.0) 10 (18.5)
5 (most deprived) (%) 7 (22.6) 47 (30.5) 0 7 (13.0)
Number of microbiological samples
Cough swabs, median (IQR) 4 (2–7) 1 (0–4) < 0.001* 0 (0–2) 0 (0–0) 0.796*
Sputum samples, median (IQR) 1 (1–3) 4 (1–7) 0.002* 8 (3–10) 8 (5–10) 0.613*
Total, median (IQR) 6 (4–8) 6 (4–9) 0.987* 9 (5–10) 8 (6–10) 0.728*
Sputum producersa (%) 21 (67.7) 118 (76.6) 0.297*** 8 (100) 51 (94.4) 1.000****
BMI in kg/m2, median (IQR) 23.0 (21.3–26.0) 22.9 (20.1–30.3) 0.631* 20.8 (17.7–23.7) 22.2 (19.9–25.7) 0.163*
% predicted FEV1, median (IQR) 87 (75–94)
b 80 (61–93)b 0.292* 55.6
(40.6–81.7)c
49.6
(42.9–76.2)c
0.600*
Annual intravenous antibiotic
days,
median (IQR)
12 (0–37) 14 (0–34) 0.460* 14 (4–35) 21 (5–45) 0.575*
aA person was considered a ‘sputum producer’ if he/she provided at least one sputum sample over a one-year period
b This is the highest FEV1 in 2015, with % predicted calculated using the Knudson equation
c This is the baseline FEV1 at recruitment, with % predicted calculated using the GLI equation
*Mann–Whitney test; **Chi-squared test for trend; ***Chi-squared test; **** Fisher’s exact test
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such reasons were often triangulated with other ‘more objec-
tive’ data (e.g. high serum P. aeruginosa antibody levels) be-
fore a consensus ‘chronic P. aeruginosa’ decision was
reached. Given the challenging nature of determining
P. aeruginosa status, these data are valuable in making the
case for further work to create an approach to improve diag-
nostic consistency. Clinicians across three different specialist
adult CF centres displayed some consistency in their decision-
making but they did not always agree with the Leeds criteria in
diagnosing P. aeruginosa status, and the extent of this dis-
agreement was influenced by the case mix.
The lack of a ‘gold standard’ for P. aeruginosa status
means that different clinical trials evaluating treatments
for people with chronic P. aeruginosa (e.g. nebulised
levofloxacin and tobramycin inhalation powder) used
different eligibility criteria [25, 26]. The exact definition
of P. aeruginosa status is, perhaps, not crucial in a drug
trial whereby people with uncertain P. aeruginosa status
would be distributed randomly across different arms of
the trial. However, an accurate P. aeruginosa status is
crucial for a nebuliser adherence trial such as ACtiF
because P. aeruginosa status influences the prescription
of inhaled therapies and determines normative adherence
(which is an outcome measure in the ACtiF pilot) [6,
27]. The challenge of determining P. aeruginosa status
among adults with CF has clear parallels with the prob-
lem posed by exacerbation and identifies the need for a
pragmatic set of guidelines that can be easily applied in
clinical trials, in a similar way in which the Fuchs or
EPIC criteria have been used to determine the presence
of pulmonary exacerbations [28]. Both the Fuchs and
EPIC criteria emerged out of the necessity to standard-
ise the definition of exacerbations in multi-centre trials.
Neither the Fuchs nor EPIC criteria would constitute the
‘gold standard’, but, nevertheless, provide an agreed
definition that allows exacerbation to be diagnosed as
a valid outcome in multi-centre clinical tr ials.
Likewise, a standardised P. aeruginosa status definition
will be important in a multi-centre nebuliser adherence
trial such as the ACtiF study, which uses ‘normative
adherence’ [6] as one of the secondary outcomes. Of
note, both the Fuchs and EPIC criteria consist of ‘ob-
jective’ evidence, e.g. acute FEV1 decline, and more
‘subjective’ evidence, e.g. change in symptoms because
Table 6 Comparison of the P. aeruginosa status according to the Leeds criteria vs. clinicians’ decision, stratified according to different subgroups
Sheffield dataset (n = 185) ACtiF pilot dataset (n = 62)
Number
of adults
in each
subgroup
(%)
Agreement between
the Leeds criteria
and clinicians’
decision, Cohen’s
kappa coefficient
(95% CI)
‘Sensitivity’ of the Leeds
criteria in diagnosing chronic
P. aeruginosa compared to
clinicians’ decision (95% CI)
Number
of adults
in each
subgroup
(%)
Agreement between
the Leeds criteria
and clinicians’
decision, Cohen’s
kappa coefficient
(95% CI)
‘Sensitivity’ of the Leeds
criteria in diagnosing chronic
P. aeruginosa compared to
clinicians’ decision (95% CI)
Overall 185 0.72 (0.64–0.80) 0.75 (0.66–0.83) 62 0.82 (0.74–0.89) 0.85 (0.69–0.95)
Subgroups based on
microbiology samples
Cough swabs >
sputum samples
(the ‘more
difficult to
agree’
subgroup)
77 (41.6) 0.54 (0.40–0.69) 0.38 (0.20–0.59) 5 (8.1) N/A (all 5 adults
were ‘no
P. aeruginosa’
according to the
Leeds criteria)
N/A (all 5 adults
were non-chronic
P. aeruginosa)
Sputum samples ≥
cough swabs
(the ‘easier to
agree’
subgroup)
108 (58.4) 0.78 (0.67–0.90) 0.88 (0.78–0.94) 57 (91.9) 0.78 (0.64–0.93) 0.85 (0.69–0.95)
Subgroups based on age
Age ≤ 25 years
(the ‘more
difficult to
agree’
subgroup)
85 (45.9) 0.60 (0.47–0.72) 0.53 (0.34–0.69) 24 (38.7) 0.72 (0.48–0.95) 0.75 (0.43–0.95)
Age > 25 years
(the ‘easier to
agree’
subgroup)
100 (54.1) 0.82 (0.72–0.93) 0.88 (0.78–0.95) 38 (61.3) 0.82 (0.65–0.98) 0.91 (0.71–0.99)
Eur J Clin Microbiol Infect Dis
exacerbations do not always present in the same way
[28]. A similar approach might enable a consensus
group to add additional parameters to the Leeds criteria.
Our findingsmay also have clinical implications. Preventative
inhaled therapies are crucial to maintain health among people
with CF [5], and the most potent of these are inhaled antibiotics.
The decision to initiate inhaled antibiotics is predominantly driv-
en by P. aeruginosa status. The results of this study suggest that
P. aeruginosa status may be more difficult to define among
younger adults who are particularly vulnerable to lung function
decline [29]. Inadequate prescription of treatment (‘therapeutic
inertia’) is the second biggest cause of treatment under-utilisation
after low adherence [30]. It is crucial to ensure that a diagnosis of
chronic P. aeruginosa is not inadvertently missed among youn-
ger adults who are likely to have accumulated less lung damage,
have lower P. aeruginosa density in their lungs and reduced
likelihood of culturing P. aeruginosa with standard respiratory
samples. A consensus approach to the challenge of diagnosing
chronic P. aeruginosa in this age group might prompt helpful
approaches; for example, perhaps younger adults with CF should
be monitored more intensively (e.g. supplementing standard re-
spiratory samples with regular serum P. aeruginosa antibodies).
The next step of this research is to use formal con-
sensus methods to integrate the expertise of clinicians
from a greater number of adult CF centres in order to
explicitly develop a pragmatic definition of chronic
P. aeruginosa infection that moves beyond solely de-
pending on standard microbiological results. Such a
consensus exercise has been successfully completed,
and a paper describing the results is in preparation.
Given that a perfectly sensitive and specific test for chronic
P. aeruginosa is unlikely to become routinely available in the
near future, we anticipate that a carefully developed set of
consensus criteria to define chronic P. aeruginosa infection
has the potential to contribute to clinical practice and bring
similar benefits to those brought by the Fuchs criteria as a tool
for structuring investigations around exacerbations.
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